Protein expression profiling identifies cyclophilin A as a molecular target in Fhit-mediated tumor suppression

Shuho Semba1, Kay Huebner

  • 1Comprehensive Cancer Center and Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University, Room 455C, Wiseman Hall, 410 West 12th Avenue, Columbus, 43210, USA.

Insights

Loss of fragile histidine triad (Fhit) protein suppresses tumors by downregulating cyclophilin A, a key factor in cell cycle progression. Restoring Fhit halts cancer cell growth by targeting cyclophilin A signaling.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Proteomics

Background:

  • Fragile histidine triad (Fhit) protein acts as a tumor suppressor, but its specific signaling pathways remain unclear.
  • Fhit's tumor suppressor function is diminished by a Y114F substitution, indicating the importance of this residue.

Purpose of the Study:

  • To identify proteins involved in Fhit-mediated tumor suppression using a proteomic approach.
  • To investigate the role of cyclophilin A in Fhit's tumor suppressor pathway.

Main Methods:

  • Proteomic analysis of lung cancer cells expressing wild-type and Y114F mutant Fhit.
  • Western blotting to assess protein expression levels.
  • Cell cycle analysis to evaluate the impact on cell cycle progression.

Main Results:

  • Cyclophilin A protein levels were significantly decreased in cells expressing wild-type Fhit compared to Y114F mutant Fhit.
  • Loss of Fhit expression led to increased cyclophilin A, which in turn promoted cyclin D1 and Cdk4 expression, driving cell cycle progression.
  • Restoration of Fhit expression down-regulated cyclophilin A, inhibiting cell cycle progression at the G1-S transition.
  • Fhit's modulation of calcineurin phosphatase activity was reversed by cyclophilin A, highlighting cyclophilin A as a downstream target.

Conclusions:

  • Cyclophilin A is a downstream target in the Fhit-mediated tumor suppression pathway, specifically affecting cell cycle progression at the late G1 phase.
  • Understanding Fhit signaling and its protein effectors, like cyclophilin A, may reveal new therapeutic targets for lung cancer.